MX2018006986A - Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis. - Google Patents

Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis.

Info

Publication number
MX2018006986A
MX2018006986A MX2018006986A MX2018006986A MX2018006986A MX 2018006986 A MX2018006986 A MX 2018006986A MX 2018006986 A MX2018006986 A MX 2018006986A MX 2018006986 A MX2018006986 A MX 2018006986A MX 2018006986 A MX2018006986 A MX 2018006986A
Authority
MX
Mexico
Prior art keywords
natriuretic peptide
type natriuretic
peptide variants
treat osteoarthritis
osteoarthritis
Prior art date
Application number
MX2018006986A
Other languages
English (en)
Inventor
K Pinkstaff Jason
A O'neill Charles
M Oppeneer Todd
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of MX2018006986A publication Critical patent/MX2018006986A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al uso de variantes del péptido natriurético tipo C (CNP) para tratar la osteoartritis, para mejorar uno o más síntomas de la osteoartritis, y para tratar trastornos que tengan un componente de osteoartritis.
MX2018006986A 2015-12-08 2016-12-08 Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis. MX2018006986A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562264682P 2015-12-08 2015-12-08
PCT/US2016/065520 WO2017100400A2 (en) 2015-12-08 2016-12-08 Use of c-type natriuretic peptide variants to treat osteoarthritis

Publications (1)

Publication Number Publication Date
MX2018006986A true MX2018006986A (es) 2018-09-05

Family

ID=59013378

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006986A MX2018006986A (es) 2015-12-08 2016-12-08 Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis.

Country Status (17)

Country Link
US (2) US11202819B2 (es)
EP (2) EP4019038A3 (es)
JP (1) JP7104625B2 (es)
KR (1) KR20180088459A (es)
CN (1) CN108697766A (es)
AU (2) AU2016365751B2 (es)
CA (1) CA3007315A1 (es)
DK (1) DK3386531T3 (es)
ES (1) ES2901769T3 (es)
HR (1) HRP20211908T1 (es)
HU (1) HUE057083T2 (es)
IL (1) IL259690B2 (es)
MX (1) MX2018006986A (es)
PL (1) PL3386531T3 (es)
PT (1) PT3386531T (es)
RU (2) RU2759679C2 (es)
WO (1) WO2017100400A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017118707A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
HRP20221339T1 (hr) 2016-01-08 2023-01-06 Ascendis Pharma Growth Disorders A/S Cnp predlijekovi s učvršćenjem nosača na cikličkom dijelu peptida
IL293979B1 (en) 2016-01-08 2024-04-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with increased NEP stability
EP3400021A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
MX2018008061A (es) 2016-01-08 2018-08-23 Ascendis Pharma Growth Disorders As Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
AU2017205693B2 (en) 2016-01-08 2022-03-31 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
CA3037448A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release cnp agonists
CN112752556A (zh) * 2018-04-27 2021-05-04 雷米生物科学公司 新的医疗装置、递送运载体及其制造
US20220118053A1 (en) * 2019-02-11 2022-04-21 Ascendis Pharma Growth Disorders A/S Dry Pharmaceutical Formulations of CNP Conjugates
WO2022240936A1 (en) * 2021-05-11 2022-11-17 Texas Tech University System Targeted selenium conjugates as countermeasures for pathogenic viruses and cells
TW202334188A (zh) * 2021-12-07 2023-09-01 美商拜奧馬林製藥公司 Ｃｎｐ療法
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
EP3446711A1 (en) * 2004-03-31 2019-02-27 Kazuwa Nakao Composition for increasing body height
WO2005094889A1 (ja) 2004-03-31 2005-10-13 Chugai Seiyaku Kabushiki Kaisha 関節炎症治療剤又は予防剤
US8377884B2 (en) 2007-11-21 2013-02-19 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptides
PE20120792A1 (es) 2009-05-20 2012-07-27 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
EP2658979B1 (en) * 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof

Also Published As

Publication number Publication date
HRP20211908T1 (hr) 2022-03-04
RU2018124600A3 (es) 2020-01-13
IL259690B (en) 2022-10-01
DK3386531T3 (da) 2022-01-03
JP2019505486A (ja) 2019-02-28
CN108697766A (zh) 2018-10-23
EP4019038A2 (en) 2022-06-29
AU2016365751A1 (en) 2018-06-21
EP3386531A2 (en) 2018-10-17
EP3386531B1 (en) 2021-10-13
AU2024201852A1 (en) 2024-04-11
JP7104625B2 (ja) 2022-07-21
WO2017100400A3 (en) 2017-10-26
AU2016365751B2 (en) 2023-12-21
HUE057083T2 (hu) 2022-04-28
IL259690A (en) 2018-07-31
EP4019038A3 (en) 2022-09-28
WO2017100400A2 (en) 2017-06-15
RU2018124600A (ru) 2020-01-13
IL259690B2 (en) 2023-02-01
PT3386531T (pt) 2021-12-29
ES2901769T3 (es) 2022-03-23
US20220160836A1 (en) 2022-05-26
RU2759679C2 (ru) 2021-11-16
KR20180088459A (ko) 2018-08-03
CA3007315A1 (en) 2017-06-15
US11202819B2 (en) 2021-12-21
PL3386531T3 (pl) 2022-02-28
RU2021132347A (ru) 2022-03-24
US20190247467A1 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
MX2018006986A (es) Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis.
PH12018502664A1 (en) Variant adeno-associated viruses and methods of using
PH12017502180A1 (en) Tau-binding antibodies
MX2023002973A (es) Uso de variantes de peptido natriuretico de tipo c para tratar displasia esqueletica.
MX2020003425A (es) Tratamiento de trastornos inflamatorios.
MY197345A (en) Antibody molecules to april and uses thereof
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
NZ730865A (en) Peptides having anti-inflammatory properties
MD4801B1 (ro) Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
PH12017502207A1 (en) Tau-binding antibodies
TN2017000099A1 (en) Triazolopyrazinones as pde1 inhibitors.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
PH12017501990A1 (en) Imidazopyrazinones as pde1 inhibitors
MX2017012654A (es) Variantes de protoxina-ii y metodos de uso.
PH12017501864A1 (en) Compositions and methods for treating autism
AU363512S (en) Riser
MX2017011170A (es) Peptidos para inhibir la angiogenesis.
MX2016015280A (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MX2020003551A (es) Metodos de tratamiento de dolor agudo o cronico.
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
GB201707280D0 (en) Mediated per to peer transaction systems and methods
UA104214U (ru) Применение метода определения диастолической дисфункции сердца как способа определения порога толерантности к физическим нагрузкам
AU365764S (en) Wire balustrade connection fitting